Colorectal carcinoma (CRC) is one of the most frequent tumours in Italy and worldwide. In patients with metastatic CRC, chemotherapy has usually a palliative intent, aiming at obtaining a symptoms control, preserving quality of life (QoL), and prolonging overall survival (OS). Until the recent introduction into the clinical practice of targeted therapies, folinic acid (FA)-modulated 5-fl uorouracil (5FU) given as i.v. bolus, or as i.v. bolus plus 24-h infusion, either alone or combined with irinotecan or oxaliplatin, represented the standard front-line treatment for this disease. Actually, doublets were reported to signifi cantly increase the response rate (RR), and to prolong the progression-free survival (PFS), in comparison with single-agent FA/5FU, while their impact on OS was controversial [1] [2] [3] [4] [5] [6] [7] .
In the absence of a signifi cant prolongation of OS, the improvement or preservation, or the delay in deterioration, of quality of life (QoL) may represent a clinically relevant end-point in the management of incurable cancer patients [8, 9] . Furthermore, the baseline assessment of QoL may contribute to a comprehensive multi-dimensional evaluation of patients, giving also some prognostic information on their outcome [10, 11] . Moreover, the longitudinal evaluation of QoL may help the trade-off between regimens that are unlikely to produce different OS.
Unfortunately, no striking advantage in QoL of patients was noted in trials comparing regimens that were similarly effective [12] [13] [14] [15] [16] , while a delay in worsening of some specifi c symptoms [1] , or in the global QoL score [2, 3] , has been reported in favour every two months during treatment (before each planned consultation and disease status assessment). The EORTC QLQ-C30 scores were calculated using the recommended EORTC procedures [19] .
Only patients who completed the baseline questionnaire were included in the present analysis. The Kaplan-Meier method estimated the PFS and OS probabilities. Univariate and multivariate analyses were performed for testing the independent relationship of clinical characteristics and PF score with OS, PFS and RR. All tests were stratifi ed by arms of treatment. Baseline socio-demographic characteristics were initially assessed in a univariate model: sex (male vs. female), weight loss (<5% vs. ≥5% of body weight), primary site (colon vs. rectum), previous surgery of the primary (yes vs. no), previous adjuvant chemotherapy (yes vs. no), and presence of synchronous metastasis (yes vs. no) were considered as discrete variables, while age, PS, serum alkaline phosphatase, serum CEA level, and number of disease sites were included as continuous variables. The signifi cant predictors from this univariate analysis were implemented in the multivariate model, and a backward selection was applied to eliminate nonsignifi cant parameters. Thereafter, the PF scores of patients, considered as a continuous variable, were added to the model.
For exploratory purpose, the highest and lowest quartile of the distribution of PF score were selected to split the whole population in three numerically comparable groups of patients: those with a score superior or equal to the highest quartile (high score), those with a score inferior to the lowest quartile (low score), and those with a score included between the highest and the lowest quartile (intermediate score). The estimated PFS and OS curves of these three groups were compared with the log-rank test, while their correlation with the ECOG PS score was assessed by means of a Spearman test.
Results
Three hundred and ten of 322 (96%) patients enrolled in SICOG trial 0401 completed the baseline QoL questionnaire and were included in the present analysis. Socio-demographic and clinical characteristics are reported in Table I , according to arm of treatment. It should be noted that, due to absence of upper age-limit for accrual into this trial, 36% patients were ≥ 70 years old. Conversely, only 11 patients had a PS of 2. Fifty-two percent of patients had two or more sites of disease.
Most baseline characteristics were signifi cantly associated with OS at univariate analysis. However, multivariate analysis showed that OS was negatively of doublets when compared with single-agent FA/5FU regimens.
We have recently conducted a multicentre randomised phase III trial (SICOG 0401) with the aim of comparing the OS of patients with MCRC treated in fi rst-line with the combination of oxaliplatin plus either FA/5FU (OXAFAFU regimen) or capecitabine (OXXEL regimen) [16] . Prospective assessment and comparison of QoL between arms of treatment was a secondary end-point of this study, and the recruited population had the power to demonstrate a pre-specifi ed clinically meaningful difference in QoL [17, 18] . Actually, no differences in RR (33% vs. 34%), PFS (median, 6.5 vs. 6.6 months) and OS (median, 17.1 vs. 16.0 months) were observed between the two arms of this trial. Overall, the OXXEL regimen was better tolerated. Excluding constipation and fi nancial item scores, no other signifi cant differences in single domains, or in global health status, were observed between the two arms during the whole treatment.
Given these results, we planned to investigate the baseline socio-demographic and clinical characteristics of this population, with the aim of ascertain their prognostic value on PFS and OS, and their predictive value on RR. Furthermore, we wondered whether QoL assessment could also add further information to this analysis. In order to avoid false positive results due to multiple testing and multicollinearity, we focused the analysis on the physical functioning (PF) score, because of its possible relationship with the performance status (PS) of patients.
Patients and methods
Three-hundred and twenty-two patients with a histologically proven diagnosis of MCRC were consecutively enrolled in the SICOG trial 0401. Patients selection criteria were previously reported [16] . Informed consent was obtained from all patients, and the trial was approved by the local ethical committee. After stratifi cation for centre, ECOG PS, and previous exposure to adjuvant chemotherapy, patients were randomly allocated to receive either oxaliplatin 85 mg/m 2 i.v. (2-h) on day 1, 6S-FA 250 mg/m 2 i.v. (2-h) followed by 5FU 850 mg/m 2 i.v. (bolus) on day 2 (OXAFAFU arm), or oxaliplatin 100 mg/m 2 i.v. (2-h) and capecitabine 1 000 mg/m 2 orally twice daily from day 1 (evening) to day 11 (morning) (OXXEL arm). Cycles were repeated every two weeks in both arms. QoL was longitudinally assessed using the EORTC Quality of life Questionnaire-Core 30 (EORTC QLQ-C30). All patients were asked to complete this form at registration in the clinic (before physical examination and random assignment), and affected only by number of metastatic sites, serum alkaline phosphatase, and PS, while it was positively affected by the previous surgical resection of the primary tumour (Table II) . Adding the baseline PF score to the model, the number of disease sites (p Ͻ 0.0001), the serum alkaline phosphatase (p ϭ 0.0057), and the PF (p ϭ 0.0007) retained an independent signifi cance, while the PS and the previous surgery were no longer signifi cant (Table III) .
OS curves according to baseline PF grouping are plotted in Figure 1 . Median OS was 19.3 (95% CI, 17.2 to 21.4) months for 111 patients with a high score, 18.0 (95% CI, 11.2 to 24.8) months for 99 patients with an intermediate score, and 12.1 (95% CI, 9.6 to 14.6) months for 100 patients with a low score. The 1-year probability of survival was 70% (95% CI, 78% to 62%), 61% (95% CI, 71% to 51%), and 51% (95% CI, 61% to 41%), respectively (p ϭ 0.0012).
Although several baseline clinical characteristics were associated with PFS at univariate analysis, only the number of metastatic sites (p ϭ 0.0001), and the Figure 2 . PFS was comparable for patients with a high (median, 7.0; 95% CI, 5.6 to 8.4 months) and an intermediate score (median, 6.7; 95% CI, 5.1 to 8.3 months), while it was slightly shorter for patients with a low score (median, 5.5; 95% CI, 4.1 to 6.9 months), but this difference was not signifi cant (p ϭ 0.1055).
Age of patients (p ϭ 0.0001), and presence of synchronous metastases (p ϭ 0.0413) were the only baseline characteristics independently associated with probability of response, while PF showed no correlation with RR. Distribution of responders according to PF grouping is reported in Table IV. There was a weak but signifi cant correlation (r ϭ 0.426, p ϭ 0.0132) between the PF groups and the PS scores (Table V) . However, it should be noted that, among 100 patients in the low PF group, 38 patients were assigned a PS score 0, and 55 patients a PS score 1.
An exploratory analysis showed that 143 of 310 (46.1%) patients received all three active cytotoxic drugs (i.e., fl uorouracil or capecitabine, oxaliplatin, and irinotecan) in the course of their disease, and that these patients lived signifi cantly longer (median, 20.9 months) than patients that did not (median, 11.1 months) (HR ϭ 0.55; 95% CI, 0.41 to 0.73, p ϭ 0.0001). Fifty-eight of 111 patients with a high PF score, 48 of 99 with an intermediate score, and 37 of 100 with a low score received all three active drugs (p ϭ 0.028).
Discussion
This retrospective analysis was conducted to investigate the independent relationship between baseline clinical characteristics and outcome of MCRC patients entered in SICOG trial 0401, and to assess whether the PF score, derived from the EORTC QLQ-C30 questionnaire fi lled-in by patients, could add further prognostic and/or predictive information.
In this analysis, the PF score was a good prognosticator of OS. Indeed, the Cox analysis confi rmed that, besides the number of disease sites, and the serum alkaline phosphatase concentration, the patient-self-reported PF was independently related with OS. It is interesting to note that, when adding this information to the multivariate model, PS of patients was no longer signifi cant, meaning that the former has a greater prognostic value that the latter.
Some hypotheses could be considered to explain this fi nding. First of all, it is possible that patients could better explicit the perception of their physical status answering to a structured and written questionnaire, which was fi lled-in before the medical visit, and without third-party conditioning, than by an informal and time-limited conversation with their attending physicians, which is often done in the presence of other people (relatives and/or care-givers). Moreover, a choice within a 4-point-scale may be Figure 1 . OS curves according to PF score groups: circles, high score (n = 111); squares, intermediate score (n = 99); triangles, low score (n = 100). Log-rank test, p = 0.0012. Figure 2 . PFS curves according to PF score groups: circles, high score (n ϭ 111); squares, intermediate score (n ϭ 99); triangles, low score (n ϭ 100). Log-rank test, p ϭ 0.1055. more sensitive than a 3-point score of the PS (it should be remembered that only patients having an ECOG PS Յ 2 were eligible for the SICOG 0401 trial). Finally, as already shown [20] , physicians usually report patients to have fewer problems/symptoms than patients themselves did. As a matter of fact, in our trial only few patients with a low PF score were assigned a PS 2. Given the lack of statistical relationship between baseline PF and activity of front-line chemotherapy (in terms of RR and PFS), we wondered why it had a negative impact on OS. The exploratory analysis we performed on the salvage treatment after failure of front-line chemotherapy showed that patients treated with all three active drugs in the course of their disease lived signifi cantly longer, and this observation is consistent with previous reports [21, 22] . Actually, more than half of patients with high PF, as opposed to about one-third of those with a lower score, received an irinotecan-based salvage treatment, and this difference was highly signifi cant. We suppose that physicians, care-givers, or patients themselves were less willing to embark on a secondline chemotherapy when the patient's physical status was likely worse than that at front-line treatment.
Other investigators have reported the prognostic signifi cance of baseline QoL in MCRC patients [20, 23, 24] , but no insights on the relationship between baseline QoL and activity of front-line chemotherapy, nor with post-progression second-line treatment, have been reported. Earlam et al. [23] investigated the correlation between OS, tumour size, and QoL, assessed with the Sickness Impact Profi le (SIP), the Rotterdam symptom checklist (RSC), and the Hospital Anxiety and Depression (HAD) scale, in 50 patients with liver only MCRC. They reported that only the physical score (from the RSC) was independently associated with OS. Maisey et al. [20] examined the EORTC QLQ-C30 questionnaire fi lled-in by 501 of 631 (79%) patients recruited into four randomized single-centre trials; they found that all domains of QoL, both functioning and symptomatic, with the only exception of the perceived fi nancial impact, were correlated with OS, and the majority of these QoL domains remained independently predictors of OS in the fi nal multivariate model. Lis et al. [24] assessed the quality of life index (QLI) in a consecutive series of 177 patients with CRC cancer in different disease stage. QLI measures global QoL and four major subscales: health and physical functioning, social and economic, psychological/spiritual, and family. They found that health and physical subscale was signifi cantly associated with OS, and this predictive effect was independent of stage and treatment.
On the contrary, Effi cace et al. [25] , who evaluated QoL by the EORTC QLQ-C30 questionnaire in 299 of 497 (60%) patients enrolled in a 3-arm multicentre randomized trial, reported that social functioning was the only domain retaining significance with OS in the multivariate analysis. Subsequently, this observation has been validated in 443 of 564 (78%) patients enrolled in another multicentre randomized trial carried-out by the same group of investigators [26] .
Turja et al. [27] reported the prognostic effect of baseline QoL on 1 253 patients enrolled in the phase III Intergroup N9741 randomized trial. These investigators also reported that a low (below the median value), or a defi cient (≤50) baseline QoL score, signifi cantly predicted a shorter OS, independently from baseline PS.
A recent comprehensive critical review has been published on cancer clinical trials that examined the relationship between patient-reported outcomes (PROs), biomedical predictors, and OS. This review retrieved 39 clinical trials carried-out in different type of cancer patients, involving 13 874 subjects. In 36 (92%) of 39 studies, at least one PRO was signifi cantly associated with OS at multivariate analysis. Global QoL and PF each predicted survival more often than other PROs, with signifi cant fi ndings in 15 and 11 studies, respectively [28] . However, although statistically signifi cant, the size of many reported effects was usually small.
In conclusion, PF derived from the EORTC QLQ-C30 questionnaire was not a good predictor for the activity of an oxaliplatin-based front-line chemotherapy in MCRC patients, but it appeared independently associated with OS. Self-reported PF and investigator-assigned PS were not totally overlapping. Therefore, baseline QoL assessment should be incorporated as a stratifi cation factor in future randomized trials comparing new regimens or strategies of treatment, namely when OS is the primary end-point. Its prospective evaluation during and after the treatment on study, together with the information on safety and activity of salvage treatments, could better elucidate the relationship between baseline QoL and OS of patients. 
